(±)-AMG 487 - CAS 473719-41-4
Catalog number:
473719-41-4
Category:
Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C32H28F3N5O4
Molecular Weight:
603.59
COA:
Inquire
Targets:
CXCR
Description:
CXCR3 antagonist; Inhibits cell migration and metastasis
Publictions citing BOC Sciences Products
  • >> More
Brife Description:
CXCR3 antagonist; Inhibits cell migration and metastasis
Appearance:
Solid powder
Synonyms:
Benzeneacetamide, N-((1R)-1-(3-(4-ethoxyphenyl)-3,4-dihydro-4-oxopyrido[2,3-d]pyrimidin-2-yl)ethyl)-N-(3-pyridinylmethyl)-4-(trifluoromethoxy)-; N-[(1R)-1-[3-(4-ethoxyphenyl)-4-oxopyrido[2,3-d]pyrimidin-2-yl]ethyl]-N-(pyridin-3-ylmethyl)-2-[4-(trifluorome
Solubility:
Soluble to 100 mM in DMSO
Storage:
Store at -20°C
MSDS:
Inquire
Quality Standard:
In-house
Quantity:
Milligrams-Grams
Melting Point:
161.2℃ (ethyl acetate heptane )
InChIKey:
WQTKNBPCJKRYPA-OAQYLSRUSA-N
InChI:
1S/C32H28F3N5O4/c1-3-43-25-14-10-24(11-15-25)40-30(38-29-27(31(40)42)7-5-17-37-29)21(2)39(20-23-6-4-16-36-19-23)28(41)18-22-8-12-26(13-9-22)44-32(33,34)35/h4-17,19,21H,3,18,20H2,1-2H3/t21-/m1/s1
Canonical SMILES:
CCOc1ccc(cc1)n2c(=O)c3cccnc3nc2[C@@H](C)N(Cc4cccnc4)C(=O)Cc5ccc(cc5)OC(F)(F)F
1.An inhibitory metabolite leads to dose- and time-dependent pharmacokinetics of (R)-N-{1-[3-(4-ethoxy-phenyl)-4-oxo-3,4-dihydro-pyrido[2,3-d]pyrimidin-2-yl]-ethyl}-N-pyridin-3-yl-methyl-2-(4-trifluoromethoxy-phenyl)-acetamide (AMG 487) in human subjects after multiple dosing.
Tonn GR1, Wong SG, Wong SC, Johnson MG, Ma J, Cho R, Floren LC, Kersey K, Berry K, Marcus AP, Wang X, Van Lengerich B, Medina JC, Pearson PG, Wong BK. Drug Metab Dispos. 2009 Mar;37(3):502-13. doi: 10.1124/dmd.108.021931. Epub 2008 Dec 16.
(R)-N-{1-[3-(4-Ethoxy-phenyl)-4-oxo-3,4-dihydro-pyrido[2,3-d]-pyrimidin-2-yl]-ethyl}-N-pyridin-3-yl-methyl-2-(4-trifluoromethoxyphenyl)-acetamide (AMG 487) is a potent and selective orally bioavailable chemokine (C-X-C motif) receptor 3 (CXCR3) antagonist that displays dose- and time-dependent pharmacokinetics in human subjects after multiple oral dosing. Although AMG 487 exhibited linear pharmacokinetics on both days 1 and 7 at the 25-mg dose, dose- and time-dependent kinetics were evident at the two higher doses. Nonlinear kinetics were more pronounced after multiple dosing. Area under the plasma concentration-time curve from 0 to 24 h [AUC((0-24 h))] increased 96-fold with a 10-fold increase in dose on day 7 compared with a 28-fold increase in AUC((0-24 h)) on day 1. These changes were correlated with time- and dose-dependent decreases in the metabolite to parent plasma concentrations, suggesting that these changes result from a decrease in the oral clearance (CL) of AMG 487 (e.
2.Sequential metabolism of AMG 487, a novel CXCR3 antagonist, results in formation of quinone reactive metabolites that covalently modify CYP3A4 Cys239 and cause time-dependent inhibition of the enzyme.
Henne KR1, Tran TB, VandenBrink BM, Rock DA, Aidasani DK, Subramanian R, Mason AK, Stresser DM, Teffera Y, Wong SG, Johnson MG, Chen X, Tonn GR, Wong BK. Drug Metab Dispos. 2012 Jul;40(7):1429-40. doi: 10.1124/dmd.112.045708. Epub 2012 Apr 19.
CYP3A4-mediated biotransformation of (R)-N-(1-(3-(4-ethoxyphenyl)-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)ethyl)-N-(pyridin-3-ylmethyl)-2-(4-(trifluoromethoxy)phenyl)acetamide (AMG 487) was previously shown to generate an inhibitory metabolite linked to dose- and time-dependent pharmacokinetics in humans. Although in vitro activity loss assays failed to demonstrate CYP3A4 time-dependent inhibition (TDI) with AMG 487, its M2 phenol metabolite readily produced TDI when remaining activity was assessed using either midazolam or testosterone (K(I) = 0.73-0.74 μM, k(inact) = 0.088-0.099 min(-1)). TDI investigations using an IC(50) shift method successfully produced inhibition attributable to AMG 487, but only when preincubations were extended from 30 to 90 min. The shift magnitude was ∼3× for midazolam activity, but no shift was observed for testosterone activity. Subsequent partition ratio determinations conducted for M2 using recombinant CYP3A4 showed that inactivation was a relatively inefficient process (r = 36).
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related CXCR Products


CAS 266359-83-5 Reparixin

Reparixin
(CAS: 266359-83-5)

An inhibitor of CXCL8 receptor, also inhibit CXCR1 and CXCR2 activation

CAS 473719-41-4 (±)-AMG 487

(±)-AMG 487
(CAS: 473719-41-4)

CXCR3 antagonist; Inhibits cell migration and metastasis

CAS 855527-92-3 NBI-74330

NBI-74330
(CAS: 855527-92-3)

A small molecule antagonist for CXCR3

CAS 55778-02-4 WZ 811

WZ 811
(CAS: 55778-02-4)

Potent CXCR2 antagonist

CTCE 9908
(CAS: 1030384-98-5)

CXCR4 antagonist; Induces mitotic catastrophe in ovarian cancer cells

CAS 110078-46-1 Plerixafor

Plerixafor
(CAS: 110078-46-1)

Plerixafor is a chemokine receptor antagonist for CXCR4 and CXCL12-mediated chemotaxis with IC50 of 44 nM and 5.7 nM, respectively.

CAS 558447-26-0 AMD-070

AMD-070
(CAS: 558447-26-0)

Potent and selective antagonist of CXCR4 (with an IC50 value of 13 nM in a CXCR4 125I-SDF inhibition binding assay)

CAS 906805-42-3 SCH 546738

SCH 546738
(CAS: 906805-42-3)

A novel, potent and non-competitive small molecule CXCR3 antagonist with Ki of 0.4 nM

CAS 473727-83-2 SCH 527123

SCH 527123
(CAS: 473727-83-2)

A potent antagonist of both CXCR1 and CXCR2 with IC50 of 42 nM and 3 nM, respectively.

Elubrixin
(CAS: 688763-64-6)

Elubrixin is a interleukin 8 inhibitor and CXCR2 selective antagonist. It is potentially useful for Inflammatory bowel disease therapies. It inhibits ex vivo ne...

CAS 473728-58-4 SCH 563705

SCH 563705
(CAS: 473728-58-4)

A potent dual CXCR2(IC50= 1.3 nM)/CXCR1(IC50= 7.3 nM) antagonist

KRH1636
(CAS: 568526-77-2)

KRH1636 is an orally active, selective and extremely potent CXC chemokine receptor 4(CXCR4) antagonist. It exhibits a potent and selective anti-HIV-1 activity. ...

AMD 3465
(CAS: 185991-24-6)

AMD 3465,a N-pyridinylmethylene monocyclam, is a selective antagonist of CXCL12/CXCR4-mediated interactions including ligand binding and receptor activation. Wi...

(±)-NBI 74330
(CAS: 473722-68-8)

Potent and selective CXCR3 antagonist

CAS 956590-23-1 UNBS5162

UNBS5162
(CAS: 956590-23-1)

A novel naphthalimide that decreases CXCL chemokine expression in experimental prostate cancers

CAS 182498-32-4 SB225002

SB225002
(CAS: 182498-32-4)

Potent and selective non-peptide inhibitor of CXCR2 with IC50 of 22 nM

NVP CXCR2 20
(CAS: 1029521-30-9)

Potent and selective CXCR2 antagonist

CAS 1873376-49-8 CXCR2-IN-1

CXCR2-IN-1
(CAS: 1873376-49-8)

CXCR2-IN-1 is a CXCR2 antagonists (pIC50= 9.3) with favorable central nervous system penetration property (Br/Bl>0.45).

CAS 185991-07-5 AMD3465 hexahydrobromide

AMD3465 hexahydrobromide
(CAS: 185991-07-5)

AMD3465 is a potent and highly selective monomacrocyclic CXCR4 antagonist (IC50= 0.75 nM). It potently inhibits HIV cell entry in vitro and causes leukocytosis ...

CAS 211096-49-0 SB 265610

SB 265610
(CAS: 211096-49-0)

Potent CXCR2 antagonist

Chemical Structure

CAS 473719-41-4 (±)-AMG 487

Quick Inquiry

Verification code

Featured Items